Navigation Links
InterMune Announces Collaboration With National Jewish Health on NIH-Supported Genetic Research in Idiopathic Pulmonary Fibrosis
Date:9/17/2009

e no treatment option."

Pulmonary fibrosis has been a major focus of research at National Jewish Health for several decades. Dr. David Schwartz and his colleagues at National Jewish Health, the University of Colorado, Vanderbilt University, and Duke University have been funded by the National Heart, Lung and Blood Institute to pursue a series of studies designed to identify the genes that predispose individuals to develop fibrosis, to develop novel approaches to classifying this disease process using genetic and molecular tools, and to develop biomarkers for this disease that will lead to earlier recognition and more effective treatment. The collaboration with InterMune helps make these studies possible and builds on the extensive clinical database that InterMune established through their work in pulmonary fibrosis.

About IPF

Idiopathic pulmonary fibrosis (IPF) is a disabling and ultimately fatal disease that affects approximately 250,000 people in the United States and Europe combined, with approximately 30,000 new cases reported per year in each of the United States and Europe. IPF is characterized by inflammation and scarring (fibrosis) in the lungs, hindering the ability to process oxygen and causing shortness of breath (dyspnea) and cough and is a progressive disease, meaning that over time, lung scarring and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a five-year survival rate of approximately 20%. Patients diagnosed with IPF are usually between the ages of 40 and 70, with a median age of 63 years and the disease tends to affect slightly more men than women. There are no medicines approved by the FDA or EMEA for the treatment of IPF.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... efficiency and data storage may someday run ... polarizations to read and write digital information, ... technology. But ferroelectrics must first overcome a ... habit of "forgetting" stored data. , ... Energy,s Brookhaven National Laboratory have discovered nanoscale ...
(Date:8/18/2014)... According to the new ... (Municipal Wastewater Treatment and Industrial Wastewater Treatment), By ... By Configuration (Internal/Submerged and External/Sidestream), and By Region-Trends ... market for membrane bioreactor systems is projected to ... CAGR of 15.28% between 2014 and 2019. ...
(Date:8/18/2014)... 2014 China is increasingly being ... clinical research industry. Clinicaltrial.gov statistics highlight the popularity ... aging population; a high increase in infectious diseases; ... populated pool of patients and a track record ... points, China also presents challenges for the clinical ...
(Date:8/16/2014)... Arlington has received a $229,214 grant from the Walmart ... testing system that would cut the manufacturing costs of ... United States that were formerly built overseas. , The ... announcement of $4 million in awards to seven research ... in Denver made possible through the collaboration between Walmart, ...
Breaking Biology Technology:Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 2Membrane Bioreactor Systems Market Worth $2,927 Million by 2019 3China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2UT Arlington receives Walmart, Walmart Foundation innovation grant 2UT Arlington receives Walmart, Walmart Foundation innovation grant 3
... 16 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: ... company focused on endocrine therapy and oncology, today announced ... its partner and licensee for perifosine in the North ... from the U.S. Food and Drug Administration (FDA) for ...
... , , The ... , , WASHINGTON, Sept. 16 The Foundation ... national animal research education campaign. Since 2004, public support for humane ... points. The ResearchSaves campaign is designed to counter this drop in ...
... , NEW HAVEN, Conn., Sept. 16 Rib-X ... commercialization of novel drugs for the treatment of multi-antibiotic resistant ... the Company,s Board of Directors, succeeding Joseph Amprey, MD, Ph.D. ... of MedImmune, Chief Executive Officer of AstraZeneca North America, and ...
Cached Biology Technology:AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 2AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma 3Biomedical Research Organization Launches Groundbreaking National TV Campaign 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 2Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors 3
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... Scientists at the Houston Methodist Research Institute have figured ... using a pipette -- a common laboratory tool that,s ... preliminary test results in a recent issue of the ... "Studying single cells and their unique functions has become ... faculty member Lidong Qin, Ph.D., the project,s principal investigator. ...
(Date:8/19/2014)... awarded a nearly $40,000 grant from the National Center ... the National Park Service (NPS) and U.S. Department of ... of the energy efficiency and cost effectiveness of radiant ... , Radiant barriers are reflective thermal insulations commonly fitted ... reducing the amount of heat emitted in the direction ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3
... the release of GeneLinker(TM) Gold and Platinum ... and Proteomics Analysis,Software products.,"The new releases are ... data, a high priority for many of ... Protein Biomarker Package into the,latest versions of ...
... will be brought to the marketplace, giving laboratories ... Technology Transfer GmbH (EMBLEM), the commercial entity of ... that it has signed a licensing deal with ... technology called SPIM (Selective Plane Illumination Microscopy). , ...
... There's a,paradigm in life science and drug development : ... occasions I've,seen very promising drugs candidates or related research ... it, even if millions would have,been saved worldwide. The ... drug candidate that affect a "profitable" disease in addition ...
Cached Biology News:Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 3The transparent organism: EMBLEM and Carl Zeiss give labs a unique look at life 2Finding Cures For Tropical Diseases: Is Open Source An Answer? 2
PFK-2 car (P-17)...
... contains 5 ml Dynabeads Epoxy (4.5 m). ... (epoxy) reactive groups. Ideal for coupling of ... hydrophobically on initial coupling with covalent binding ... and sulphydryll groups (SH)) occurring within 16-20 ...
LTBP-2 (7B10)...
... [198C679.2.1] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
Biology Products: